Novavax On The Verge of Making History?

The small vaccinemaker that faced an existential threat is slated to receive up to $2 billion from the U.S. government and a nonprofit organization to develop and manufacture a coronavirus vaccine, says an article published in ScienceMag.

A turnover like no one imagined

Eighteen months ago, a small vaccine maker here called Novavax faced an existential threat: delisting by the NASDAQ stock index. On the heels of a second failed vaccine trial in less than 3 years, the firm’s shares had plunged to...

Leave a Comment

Join Our Newsletter
Enter your email to receive a weekly round-up of shipping news.